Terry Stevens-Ayers

Terry Stevens-Ayers

Auto-generated profile, based on publicly available information

Terry Stevens-Ayers

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
RERachel T. Eguia
Rachel T. Eguia
KCKatharine Crawford
Katharine Crawford
TSTerry Stevens-Ayers
Terry Stevens-Ayers
LKLaurel Kelnhofer-Millevolte
Laurel Kelnhofer-Millevolte
AGAlexander L. Greninger
Alexander L. Greninger
JBJesse Bloom
Jesse Bloom
There is intense interest in antibody immunity to coronaviruses. However, it is unknown if coronaviruses evolve to escape such immunity, and if so, how rapidly. Here we address this question by characterizing the historical evolution of human coronavirus 229E. We identify human sera from the 1980s and 1990s that have neutralizing titers against contemporaneous 229E that are comparable to the anti-SARS-CoV-2 titers induced by SARS-CoV-2 infection or vaccination. We test these sera against 229E strains isolated after sera collection, and find that neutralizing titers are lower against these “future” viruses. In some cases, sera that neutralize contemporaneous 229E viral strains with titers >1:100 do not detectably neutralize strains isolated 8–17 years later. The decreased neutralization of “future” viruses is due to antigenic evolution of the viral spike, especially in the receptor-binding domain. If these results extrapolate to other coronaviruses, then it may be advisable to periodically update SARS-CoV-2 vaccines.

8 June 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
CWCarla S. Walti
Carla S. Walti
EKElizabeth Krantz
Elizabeth Krantz
JMJoyce Maalouf
Joyce Maalouf
JBJim Boonyaratanakornkit
Jim Boonyaratanakornkit
JKJacob Keane-Candib
Jacob Keane-Candib
JHJoshua aiden Hill
Joshua aiden Hill
BACKGROUND: Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies. METHODS: We conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen–targeted (BCMA-targeted) CAR-T cell therapy recipients at least 6 months posttreatment and in remission. We measured pathogen-specific IgG against 12 vaccine-preventable infections and the number of viral and bacterial epitopes to which IgG was detected (“epitope hits”) using a serological profiling assay. The primary outcome was the proportion of participants with IgG levels above a threshold correlated with seroprotection for vaccine-preventable infections. RESULTS: We enrolled 65 children and adults a median of 20 months after CD19- ( n = 54) or BCMA- ( n = 11) CAR-T cell therapy. Among 30 adults without IgG replacement therapy (IGRT) in the prior 16 weeks, 27 (90%) had hypogammaglobulinemia. These individuals had seroprotection to a median of 67% (IQR, 59%–73%) of tested infections. Proportions of participants with seroprotection per pathogen were comparable to population-based studies, but most individuals lacked seroprotection to specific pathogens. Compared with CD19-CAR-T cell recipients, BCMA-CAR-T cell recipients were half as likely to have seroprotection (prevalence ratio, 0.47; 95% CI, 0.18–1.25) and had fewer pathogen-specific epitope hits (mean difference, –90 epitope hits; 95% CI, –157 to –22). CONCLUSION: Seroprotection for vaccine-preventable infections in adult CD19-CAR-T cell recipients was comparable to the general population. BCMA-CAR-T cell recipients had fewer pathogen-specific antibodies. Deficits in both groups support the need for vaccine and immunoglobulin replacement therapy studies. FUNDING: Swiss National Science Foundation (Early Postdoc Mobility grant P2BSP3_188162), NIH/National Cancer Institute (NIH/NCI) (U01CA247548 and P01CA018029), NIH/NCI Cancer Center Support Grants (P30CA0087-48 and P30CA015704-44), American Society for Transplantation and Cellular Therapy, and Juno Therapeutics/BMS.

4 January 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
EDElizabeth R Duke
Elizabeth R Duke
BWBrian D. Williamson
Brian D. Williamson
BBBhavesh Borate
Bhavesh Borate
JGJonathan L. Golob
Jonathan L. Golob
CWChiara Wychera
Chiara Wychera
MBMichael Boeckh
Michael Boeckh
BACKGROUND. Viral load (VL) surrogate endpoints transformed development of HIV and hepatitis C therapeutics. Surrogate endpoints for CMV-related morbidity and mortality could advance development of antiviral treatments. Although observational data support using CMV VL as a trial endpoint, randomized controlled trials (RCTs) demonstrating direct associations between virological markers and clinical endpoints are lacking. METHODS. We performed CMV DNA PCR on frozen serum samples from the only placebo-controlled RCT of ganciclovir for early treatment of CMV after hematopoietic cell transplantation (HCT). We used established criteria to assess VL kinetics as surrogates for CMV disease or death by weeks 8, 24, and 48 after randomization and quantified antiviral effects captured by each marker. We used ensemble-based machine learning to assess the predictive ability of VL kinetics and performed this analysis on a ganciclovir prophylaxis RCT for validation. RESULTS. VL suppression with ganciclovir reduced cumulative incidence of CMV disease and death for 20 years after HCT. Mean VL, peak VL, and change in VL during the first 5 weeks of treatment fulfilled the Prentice definition for surrogacy, capturing more than 95% of ganciclovir’s effect, and yielded highly sensitive and specific predictions by week 48. In the prophylaxis trial, the viral shedding rate satisfied the Prentice definition for CMV disease by week 24. CONCLUSIONS. Our results support using CMV VL kinetics as surrogates for CMV disease, provide a framework for developing CMV preventative and therapeutic agents, and support reductions in VL as the mechanism through which antivirals reduce CMV disease. FUNDING. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

11 March 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SJSrirama Josyula
Srirama Josyula
MPMargot J. Pont
Margot J. Pont
SDSayan Dasgupta
Sayan Dasgupta
XSXiaoling Song
Xiaoling Song
STSushma Thomas
Sushma Thomas
JHJoshua aiden Hill
Joshua aiden Hill
Chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen (BCMA-CARTx) are an emerging treatment for relapsed or refractory multiple myeloma (R/R MM). Characterize the epidemiology of infections, risk factors for infection, and pathogen-specific humoral immunity in patients receiving BCMA-CARTx for R/R MM. We performed a retrospective cohort study in 32 adults with R/R MM enrolled in two single-institution phase 1 clinical trials of BCMA-CARTx administered after lymphodepleting chemotherapy alone (n=22) or with (n=10) a gamma secretase inhibitor (GSI). We tested serum prior to and up to approximately 180 days after BCMA-CARTx for measles-specific IgG and for any viral-specific IgG using a systematic viral epitope scanning assay to describe the kinetics of total and pathogen-specific IgG levels pre- and post-BCMA-CARTx. We identified microbiologically documented infections to determine infection incidence and used Poisson regression to explore risk factors for infections within 180 days after BCMA-CARTx. Most individuals developed severe neutropenia, lymphopenia and hypogammaglobulinemia after BCMA-CARTx. Grade ≥3 cytokine release syndrome (CRS; Lee criteria) occurred in 16% of participants; corticosteroids and/or tocilizumab were administered to 50% of participants. Before BCMA-CARTx, 28/32 (88%) participants had an IgG <400 mg/dL and only 5/27 (19%) had seropositive measles antibody titers. After BCMA-CARTx, all participants had IgG <400 mg/dL and declining measles antibody titers; of the 5 individuals with baseline seropositive levels, 2 remained above the seroprotective threshold post-treatment. Participants with IgG MM (n=13) had significantly fewer antibodies to a panel of viral antigens compared to participants with non-IgG MM (n=6), both prior to and after BCMA-CARTx. In the first 180 days after BCMA-CARTx, 17 (53%) participants developed 23 infections, in whom 13/23 (57%) infections were mild-to-moderate viral infections. Serious infections were more frequent in the first 28 days. Infections appeared to be more common in individuals with higher-grade CRS. Individuals with R/R MM have substantial deficits in humoral immunity. These data demonstrate the importance of plasma cells in maintaining long-lived pathogen-specific antibodies and suggest that BCMA-CARTx recipients should have ongoing surveillance for late-onset infections. Most infections were mild-moderate severity viral infections. The early infection incidence appears to be lower than reported after CD19-CARTx for B-cell neoplasms, which may be due to differences in patient/disease characteristics and regimen related toxicities.

1 December 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
FLFang Yun Lim
Fang Yun Lim
SKSoo-Young Kim
Soo-Young Kim
KKKarisma N. Kulkarni
Karisma N. Kulkarni
RBRachel L. Blazevic
Rachel L. Blazevic
LKLouise E. Kimball
Louise E. Kimball
AWAlpana Waghmare
Alpana Waghmare

22 July 2025 in Journal of Virology
Verified
Journal Article
Open access
CSCassandra A. L. Simonich
Cassandra A. L. Simonich
TMTeagan E. McMahon
Teagan E. McMahon
XJXiaohui Ju
Xiaohui Ju
TYTimothy C. Yu
Timothy C. Yu
NBNatalie Brunette
Natalie Brunette
JBJesse Bloom
Jesse Bloom
Vaccines and monoclonal antibodies targeting the respiratory syncytial virus (RSV) fusion protein (F) have recently begun to be widely used to protect infants and high-risk adults. Some other viral proteins evolve to erode polyclonal antibody neutralization and escape individual monoclonal antibodies. However, the impact of RSV F evolution on antibody neutralization is not yet thoroughly understood. Here, we develop an experimental system for measuring neutralization titers against RSV F using pseudotyped lentiviral particles. This system is easily adaptable to evaluate neutralization of relevant clinical strains. We apply this system to demonstrate that the natural evolution of RSV F leads to escape from some monoclonal antibodies, but at most modestly affects neutralization by polyclonal serum antibodies. Overall, our work sheds light on RSV antigenic evolution and describes a tool to measure the ability of antibodies and sera to neutralize contemporary RSV strains. IMPORTANCE: We describe an efficient approach to measure how antibodies inhibit infection by historical and recent human strains of respiratory syncytial virus (RSV). This approach is useful for understanding how viral evolution affects antibody immunity. We apply this approach to demonstrate that RSV evolution can escape some monoclonal antibodies, but polyclonal serum antibodies are less impacted by viral evolution. This information is relevant given the recent development of RSV preventative measures, including monoclonal antibodies and vaccines.